Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left" rowspan="2">Variables</td><td align="center" colspan="2">Absence on TD-OCT</td></tr><tr class="thead"><td align="center">Presence on SD-OCT</td><td align="center">Absence on SD-OCT</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Subretinal fluid</td><td align="center">8 patients (16.3%)</td><td align="center">41 patients (83.7%)</td></tr><tr><td align="left">Intraretinal cysts, or fluid</td><td align="center">10 patients (20.4%)</td><td align="center">39 patients (79.6%)</td></tr><tr><td align="left">SubRPE fluid</td><td align="center">3 patients (6.1%)</td><td align="center">46 patients (93.9%)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>TD-OCT: time-domain optical coherence tomography; SD-OCT: spectral-domain optical coherence tomography; SubRPE: subretinal pigment epithelium.<br/></td></tr></table>

The findings on spectral-domain optical coherence tomography when time-domain optical coherence tomography and clinical examination showed no sign of choroidal neovascularization activation.

Journal of Ophthalmology

tab1

Table 1

Table 1: Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration? 

Table 1 | Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration? 